Last reviewed · How we verify
ASTX660
At a glance
| Generic name | ASTX660 |
|---|---|
| Also known as | Tolinapant, Treatment of ASTX660 for advanced solid tumors and lymphomas |
| Sponsor | Otsuka Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas (PHASE1, PHASE2)
- A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma (PHASE1, PHASE2)
- A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL) (PHASE1)
- ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab (PHASE1)
- Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer (EARLY_PHASE1)
- Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer (PHASE1)
- Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer (PHASE1, PHASE2)
- A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASTX660 CI brief — competitive landscape report
- ASTX660 updates RSS · CI watch RSS
- Otsuka Pharmaceutical Co., Ltd. portfolio CI